Navigation Links
MMD in Medical News

Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND

...ry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for mmd may not actually match up with our external assessment, our common stock could be delisted from the Nasdaq Capital Market and other risks and challeng...

Toxic Strand Of RNA Causes Myotonic Muscular dystrophy

...hopes the research might lead to new therapies for mmd in the next few years. "If we develop a therapy to...icroscope. They also integrated an "on switch" for mmd in the mice, activated by giving them doxycycline,...TG repeats, they developed the hallmarks of type 1 mmd within a few weeks, including an inability to rela...
MMD in Medical Technology

Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs

... by Year-End - Enrollment On Track in mmd Clinical Study - ALS Expanded Access Pro...ehrig's disease. A Phase 2 trial of IPLEX(TM) in mmd is on-going and a substantial portion of the exter...e Muscular Dystrophy Association in late 2007. mmd Phase 2 trial at-a-glance: -- All sites have been...

Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy

...lopment, and maximize the market opportunities for mmd available to us." Orphan status is granted by th... years of market exclusivity upon approval for the mmd indication. In addition, Insmed is eligible for ta...e drug candidate through the regulatory process. mmd affects approximately 37,000 Americans, and nearly...
MMD in Biological News

American Chemical Society's Weekly PressPac -- Nov. 19, 2008

...most common form of muscular dystrophy in adults. mmd affects about 1 in 8,000 people. Their findings a...udy, Benjamin Miller and colleagues point out that mmd differs from typical hereditary diseases. They re...tivity and cause symptoms of the disease. Rather, mmd is caused by wayward or "toxic" strands of RNA. ...

Toxic molecule may cause most common type of muscular dystrophy

...sulin resistance. Many people don't know they have mmd until their teens or twenties. To prove the...hopes the research might lead to new therapies for mmd in the next few years. "If we develop a therapy to...croscope. They also integrated an "on switch" for mmd in the mice, activated by giving them doxycycline,...
MMD in Biological Technology

Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy

...tial Initiation of Phase II Trial for IPLEX(TM) in mmd Patients with Severe Insulin Resistance - RIC...s of testosterone. The drug was well tolerated in mmd subjects and demonstrated a safety profile consist...ional Phase II trial focused solely on a subset of mmd patients with severe insulin resistance who, based...

Insmed CEO Resigns Due to Health Concerns

...ry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for mmd may not actually match up with our external assessment, we may lack financial resources to complete development of product candidates and other risks...

Insmed Announces First Quarter 2009 Financial Results

...orward on all fronts. We continue to expect preliminary Phase 2 results in mmd before the end of the second quarter. In addition, the ALS EAP is set to e...e business and develop IPLEX(TM) may be unsuccessful, the actual market for mmd may not actually match up with our external assessment, we may lack financi...

Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule

...ry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for mmd may not actually match up with our external assessment, our common stock could be delisted from the Nasdaq Capital Market and other risks and challeng...

Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results

...ted an external assessment of the total market for mmd treatments that indicated that the market for mmd could be as high as between $800 million and $1.4 ...tinue moving ahead with our IPLEX(TM) programs for mmd and ALS. In addition, we intend to pursue a compr...

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

...ivity in the current quarter compared to last year as our phase 2 IPLEX(TM) mmd trial continues to progress. SG&A Expenses were consistent quarter over qua....0 million from the Muscular Dystrophy Association supporting the IPLEX(TM) mmd trial. This was partially offset by the absence of license income from Napo...

Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants

...d States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency, is currently being investigated in mmd and ALS. About ROP ROP is a disease of the eye that affects prematurely born babies. It is thought to be caused by disorganised growth of retinal ...

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008

...ategic financial options will ensure that we make informed decisions for moving our FOB program forward, and advancing the development of IPLEX(TM) in mmd and ALS." Revenues for the second quarter ended June 30, 2008 were $2.6 million, up from $2.3 million for the corresponding period in 2007. The incr...

Insmed Announces First Quarter 2008 Financial Results

...llan, President and CEO of Insmed. "We are aggressively pursuing a partner for our FOB program and continue to advance the development of IPLEX(TM) in mmd and ALS." Revenues for the first quarter ended March 31, 2008 were $2.3 million, up from $1.7 million for the corresponding period in 2007. The incr...

Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results

... portion of the external costs associated with the mmd trial; -- Granted Orphan Drug designation for IPLEX(TM) for the treatment of mmd by the FDA, providing the Company with, among othe...sivity upon approval of IPLEX(TM) for the mmd indication; and -- Completed an external ass...
Other Tags
(Date:12/19/2014)... December 19, 2014 Slone ... diagnostic, personalized medicine, healthcare information technology, and laboratory ... position of Chief Operating Officer. The announcement comes ... marked by a strengthened presence in Boston and ... "Leslie lives and breathes the client experience," said ...
(Date:12/19/2014)... 2014 (HealthDay News) -- Being in good shape seems to ... They looked at data from more than 57,000 Americans, including ... tests between 1991 and 2009. Those in the poorest ... high blood pressure at the start of the study, compared ... of fitness. Of the more than 8,000 people diagnosed ...
(Date:12/19/2014)... through the same U.S. airport gate, one infected passenger ... four-hour time span, illustrating just how easily the virus ... in this report were not prolonged and occurred in ... fact that measles is highly contagious," wrote a team ... the U.S. Centers for Disease Control and Prevention. ...
(Date:12/17/2014)... Unidesk Corporation today announced that ... welcomed its inaugural class in August 2013, has ... support bring your own device (BYOD) and deliver ... The solution, comprised of Citrix XenDesktop ... and storage infrastructure and Unidesk virtual ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
Other Contents